Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colesevelam versus colestyramine or loperamide for primary bile acid diarrhoea
ISRCTN89729610Phase 4Recruiting
- Sponsor
- University of Birmingham
- Start
- Nov 2026
- Modality
- Small Molecules, Device-based Delivery → Drug Delivery Systems, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
Phase 4, randomised, open-label trial in primary bile acid diarrhea (PBAD) comparing Colesevelam, Colestyramine and Loperamide (3 arms). Primary endpoint: Full clinical response at 6 months. Started Nov 2026; status: recruiting.
02
Drugs
colesevelamcholestyramineloperamide
03
Conditions
primary bile acid diarrhea (PBAD)
Beyond the preview
Go deeper on ISRCTN89729610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN89729610.